▁British 10.375
▁Bi 10.875
ote 5.59765625
ch 4.53515625
▁pl 9.34375
c 4.6171875
' 6.5703125
s 0.41455078125
▁cancer 8.7578125
▁drug 6.6875
▁Mar 9.296875
im 8.5546875
ast 7.74609375
at 6.98828125
▁Sh 7.8515625
ows 3.849609375
▁Promise 9.53125
, 6.2421875
▁But 5.875
▁F 5.57421875
aces 3.73828125
▁H 5.33984375
urd 2.341796875
les 0.857421875
▁to 5.359375
▁Be 4.97265625
come 1.4814453125
▁a 2.1328125
▁Block 6.2421875
b 1.25
uster 0.153076171875
<0x0A> 4.91796875
B 3.900390625
rit 4.12890625
ish 0.274169921875
▁Bi 3.435546875
ote 0.01534271240234375
ch 0.06915283203125
▁pl 7.08203125
c 0.0013799667358398438
▁announced 5.6484375
▁prom 6.6015625
ising 0.039337158203125
▁results 1.0068359375
▁for 1.962890625
▁its 0.759765625
▁cancer 2.75390625
▁drug 0.11090087890625
, 1.34375
▁Mar 2.87109375
im 1.2001953125
ast 0.04071044921875
at 0.006160736083984375
, 0.6005859375
▁which 1.7255859375
▁targets 4.6640625
▁the 1.771484375
▁fast 7.83203125
- 0.31103515625
g 0.2374267578125
row 0.0002663135528564453
ing 0.005474090576171875
▁matrix 12.4375
▁metal 0.299072265625
lo 0.00542449951171875
prote 0.029266357421875
in 0.07855224609375
ase 0.292236328125
▁( 1.7119140625
M 0.055877685546875
MP 0.0183868408203125
) 0.54541015625
▁market 6.76171875
. 0.53271484375
▁The 1.5625
▁drug 1.9453125
▁is 1.4892578125
▁designed 2.802734375
▁to 0.06005859375
▁in 1.9482421875
hib 0.005985260009765625
it 0.0031833648681640625
▁the 0.8017578125
▁activity 1.6123046875
▁of 0.0208892822265625
▁specific 4.80859375
▁M 0.63232421875
MP 0.002803802490234375
s 0.29443359375
▁that 1.95703125
▁promote 2.705078125
▁the 1.546875
▁growth 0.9775390625
▁and 1.4150390625
▁spread 0.53271484375
▁of 0.021087646484375
▁cancer 0.578125
▁cells 0.7919921875
. 0.404296875
▁The 1.5859375
▁drug 1.3876953125
▁is 1.2275390625
▁currently 1.29296875
▁in 0.5400390625
▁Ph 1.0126953125
ase 0.001506805419921875
▁III 2.77734375
▁clin 0.69384765625
ical 0.00044155120849609375
▁tri 0.1878662109375
als 0.00018203258514404297
, 1.724609375
▁and 0.98681640625
▁results 4.61328125
▁from 1.1083984375
▁a 2.216796875
▁recent 3.16015625
▁trial 2.47265625
▁demonstrate 5.75
▁the 1.98828125
▁drug 0.927734375
' 0.348876953125
s 0.00040411949157714844
▁potential 1.2783203125
▁as 2.00390625
▁a 0.112548828125
▁th 4.62890625
era 0.00019609928131103516
pe 0.0001119375228881836
ut 0.0003387928009033203
ic 0.005420684814453125
▁option 2.087890625
▁for 0.347412109375
▁cancer 2.6015625
▁patients 0.304443359375
. 0.366943359375
<0x0A> 0.5517578125
Mar 2.705078125
im 0.01236724853515625
ast 0.005458831787109375
at 0.0005440711975097656
▁has 2.94140625
▁been 1.4892578125
▁proven 4.40234375
▁to 0.398193359375
▁be 0.9736328125
▁effective 1.1533203125
▁against 2.119140625
▁a 1.4423828125
▁wide 1.576171875
▁range 0.389892578125
▁of 0.00182342529296875
▁can 1.2548828125
cers 0.0008096694946289062
, 0.438720703125
▁including 0.3671875
▁pan 2.423828125
cre 0.000743865966796875
atic 0.0217742919921875
▁cancer 1.296875
, 0.2303466796875
▁col 3.419921875
ore 0.00202178955078125
ct 7.891654968261719e-05
al 0.00037384033203125
▁cancer 0.06683349609375
, 0.0728759765625
▁and 1.4296875
▁met 4.56640625
ast 0.0016956329345703125
atic 0.06683349609375
▁mel 2.123046875
an 0.0003142356872558594
oma 0.0067596435546875
. 0.3017578125
▁The 0.91552734375
▁drug 0.25244140625
▁in 4.58203125
hib 0.006114959716796875
its 0.0054779052734375
▁the 0.7099609375
▁activity 0.626953125
▁of 0.0098114013671875
▁M 1.6484375
MP 0.00371551513671875
s 1.1845703125
, 1.19921875
▁which 0.40283203125
▁play 2.421875
▁critical 4.9296875
▁roles 0.00853729248046875
▁in 0.01045989990234375
▁many 4.046875
▁phys 4.76171875
i 0.00193023681640625
ological 0.06341552734375
▁processes 0.343505859375
, 0.5927734375
▁such 1.5341796875
▁as 0.0009431838989257812
▁t 2.056640625
issue 0.0009264945983886719
▁rem 1.94921875
od 0.0006680488586425781
eling 0.044189453125
, 0.66943359375
▁w 1.3037109375
ound 0.0009431838989257812
▁he 0.1422119140625
aling 6.639957427978516e-05
, 0.02496337890625
▁and 0.386962890625
▁tum 3.08203125
or 0.005527496337890625
▁invasion 1.755859375
. 0.25927734375
▁When 5.57421875
▁M 1.2626953125
MP 0.0015630722045898438
s 0.2392578125
▁are 0.10400390625
▁over 2.78125
activ 3.2265625
ated 0.00121307373046875
, 0.12890625
▁as 8.8046875
▁in 0.9892578125
▁cancer 0.86767578125
, 1.244140625
▁they 0.2359619140625
▁promote 2.34375
▁the 0.57861328125
▁growth 0.325439453125
▁and 0.2413330078125
▁spread 0.0731201171875
▁of 0.0011930465698242188
▁cancer 0.302734375
▁cells 0.0704345703125
▁by 3.095703125
▁de 3.181640625
grad 0.00743865966796875
ing 0.0013723373413085938
▁the 2.24609375
▁ext 0.1793212890625
rac 4.9233436584472656e-05
ell 0.0004458427429199219
ular 0.0013494491577148438
▁matrix 0.00978851318359375
▁( 1.2001953125
EC 0.042144775390625
M 0.0016765594482421875
) 0.958984375
▁surrounding 3.4375
▁the 0.99072265625
▁tum 0.1795654296875
or 0.026275634765625
. 0.5537109375
<0x0A> 1.33984375
The 1.6220703125
▁Ph 2.333984375
ase 0.0016336441040039062
▁III 0.044586181640625
▁clin 0.97412109375
ical 0.00019598007202148438
▁trial 0.09149169921875
▁conducted 4.796875
▁by 0.277099609375
▁British 0.1220703125
▁Bi 0.0086669921875
ote 8.547306060791016e-05
ch 0.0128021240234375
▁pl 0.15283203125
c 0.0002999305725097656
▁demonstrated 2.474609375
▁that 0.54248046875
▁Mar 0.39013671875
im 0.00107574462890625
ast 0.003231048583984375
at 0.0006461143493652344
▁can 2.83984375
▁significantly 1.9990234375
▁improve 2.48046875
▁the 0.7412109375
▁pro 2.283203125
gression 0.06573486328125
- 0.024566650390625
free 0.002044677734375
▁surv 0.085693359375
ival 0.00031304359436035156
▁rate 1.9873046875
▁of 0.96337890625
▁patients 0.3466796875
▁with 0.162109375
▁advanced 1.47265625
▁pan 0.71875
cre 0.00036072731018066406
atic 0.004974365234375
▁cancer 0.042999267578125
. 0.56591796875
▁In 2.599609375
▁the 0.880859375
▁trial 0.41552734375
, 0.020538330078125
▁patients 1.2275390625
▁who 1.458984375
▁received 0.3876953125
▁Mar 0.5654296875
im 0.0008716583251953125
ast 0.003833770751953125
at 0.0008463859558105469
▁had 1.341796875
▁a 0.2293701171875
▁median 1.720703125
▁pro 0.34033203125
gression 0.0007920265197753906
- 0.0159149169921875
free 0.0009336471557617188
▁surv 0.00397491455078125
ival 2.7179718017578125e-05
▁rate 0.6455078125
▁of 0.040985107421875
▁ 0.1376953125
2 2.259765625
. 1.3056640625
3 2.345703125
▁months 0.15771484375
, 0.556640625
▁compared 0.1778564453125
▁to 0.158203125
▁ 0.638671875
1 1.1083984375
. 0.10174560546875
6 2.388671875
▁months 0.02777099609375
▁for 0.443359375
▁patients 0.427490234375
▁who 0.202880859375
▁received 0.21484375
▁the 2.419921875
▁place 0.70166015625
bo 0.0016279220581054688
. 0.269287109375
▁The 1.3359375
▁drug 3.541015625
▁showed 3.876953125
▁similar 2.2734375
▁prom 4.35546875
ising 0.0002791881561279297
▁results 0.072021484375
▁in 0.5732421875
▁the 1.9453125
▁treatment 0.95703125
▁of 0.004878997802734375
▁other 2.798828125
▁can 0.52001953125
cers 1.4424324035644531e-05
▁as 2.865234375
▁well 0.0106964111328125
. 0.7421875
<0x0A> 0.3388671875
However 5.84765625
, 0.0026378631591796875
▁despite 3.935546875
▁Mar 4.75
im 0.001956939697265625
ast 0.0040283203125
at 0.002593994140625
' 0.033355712890625
s 0.0001316070556640625
▁potential 2.06640625
▁to 2.080078125
▁become 4.18359375
▁a 0.0821533203125
▁block 1.4228515625
b 0.0010251998901367188
uster 0.0019741058349609375
▁drug 0.302001953125
, 0.2022705078125
▁there 1.9208984375
▁are 0.12005615234375
▁significant 3.919921875
▁hur 1.79296875
d 1.4662742614746094e-05
les 7.259845733642578e-05
▁that 1.19921875
▁British 3.146484375
▁Bi 0.004489898681640625
ote 6.651878356933594e-05
ch 0.004505157470703125
▁pl 0.055389404296875
c 0.0001348257064819336
▁will 1.2001953125
▁have 0.92236328125
▁to 0.0003123283386230469
▁overcome 0.044891357421875
. 2.880859375
▁First 2.115234375
ly 2.89453125
, 0.0007781982421875
▁the 0.57421875
▁drug 0.53759765625
' 2.00390625
s 0.0001678466796875
▁pat 1.7197265625
ent 0.1629638671875
▁protection 1.4033203125
▁has 2.400390625
▁exp 0.29443359375
ired 0.00012087821960449219
, 0.484375
▁which 1.2099609375
▁means 0.60205078125
▁that 0.275634765625
▁the 2.224609375
▁drug 0.76025390625
▁is 1.5078125
▁now 1.4150390625
▁available 1.03125
▁as 3.91015625
▁a 0.68994140625
▁generic 0.09613037109375
▁drug 2.013671875
. 0.51953125
▁This 1.0947265625
▁will 2.87890625
▁make 1.2939453125
▁it 0.3212890625
▁difficult 1.15625
▁for 0.2210693359375
▁British 0.53271484375
▁Bi 0.0030612945556640625
ote 3.266334533691406e-05
ch 0.00261688232421875
▁pl 0.0114593505859375
c 3.5762786865234375e-05
▁to 0.01357269287109375
▁generate 3.00390625
▁significant 2.017578125
▁re 0.75732421875
venue 9.465217590332031e-05
▁from 0.40673828125
▁the 0.69970703125
▁drug 0.252685546875
. 0.80908203125
<0x0A> 1.763671875
Second 0.385986328125
ly 0.01218414306640625
, 9.512901306152344e-05
▁the 0.974609375
▁company 3.328125
▁will 1.3515625
▁need 1.546875
▁to 0.00737762451171875
▁demonstrate 2.74609375
▁the 0.70556640625
▁drug 1.5869140625
' 0.00751495361328125
s 4.172325134277344e-05
▁safety 1.7568359375
▁and 0.1448974609375
▁effic 0.10205078125
acy 3.075599670410156e-05
▁through 6.015625
▁further 1.8671875
▁clin 0.09063720703125
ical 2.4080276489257812e-05
▁tri 0.055908203125
als 7.152557373046875e-07
. 0.56103515625
▁While 3.994140625
▁the 0.69384765625
▁results 1.5517578125
▁from 0.61328125
▁the 0.08331298828125
▁Ph 0.302734375
ase 6.008148193359375e-05
▁III 0.0284576416015625
▁clin 0.3564453125
ical 0.00014293193817138672
▁trial 0.07440185546875
▁are 0.87548828125
▁prom 0.1832275390625
ising 1.823902130126953e-05
, 0.0039043426513671875
▁they 2.322265625
▁will 3.197265625
▁need 1.087890625
▁to 0.00577545166015625
▁be 0.026031494140625
▁rep 0.62939453125
licated 0.0012426376342773438
▁in 0.059661865234375
▁larger 1.0830078125
- 3.685546875
scale 0.0631103515625
▁tri 1.3203125
als 9.5367431640625e-07
▁to 1.046875
▁ensure 1.52734375
▁that 0.399169921875
▁the 0.455078125
▁drug 0.029052734375
▁is 0.305908203125
▁safe 0.485107421875
▁and 0.0677490234375
▁effective 0.05706787109375
▁for 1.7431640625
▁a 2.759765625
▁wider 1.1005859375
▁range 0.426513671875
▁of 0.00018966197967529297
▁patients 0.53125
. 0.027374267578125
<0x0A> 0.376953125
Th 1.94921875
ird 0.04168701171875
ly 0.0233917236328125
, 0.0004911422729492188
▁Mar 3.3046875
im 0.0004973411560058594
ast 0.001773834228515625
at 0.00019752979278564453
▁faces 2.49609375
▁competition 0.87890625
▁from 0.0184326171875
▁other 0.338623046875
▁M 2.79296875
MP 0.0017910003662109375
▁in 0.1253662109375
hib 1.3113021850585938e-06
itors 0.0672607421875
▁currently 4.90625
▁in 1.5927734375
▁development 0.96875
. 0.498779296875
▁Several 3.779296875
▁other 1.564453125
▁ph 5.07421875
arma 0.0004911422729492188
ce 0.0045623779296875
ut 4.291534423828125e-06
ical 8.368492126464844e-05
▁companies 0.0239410400390625
▁are 0.262939453125
▁developing 0.91650390625
▁M 0.80419921875
MP 0.0013532638549804688
▁in 0.00843048095703125
hib 2.181529998779297e-05
itors 0.01291656494140625
▁to 3.283203125
▁target 1.6181640625
▁cancer 2.47265625
, 0.97802734375
▁such 2.50390625
▁as 0.00023090839385986328
▁Gla 4.53125
x 0.0022907257080078125
o 0.0020885467529296875
Smith 0.0268096923828125
K 0.00829315185546875
line 0.00513458251953125
▁pl 1.09375
c 0.00016510486602783203
' 1.119140625
s 0.002044677734375
▁B 4.671875
MS 1.166015625
- 0.369384765625
2 4.11328125
7 2.365234375
5 0.4951171875
2 2.541015625
9 2.482421875
1 2.111328125
▁and 0.94970703125
▁Mill 7.0078125
en 0.0963134765625
ni 0.00061798095703125
um 0.0023021697998046875
▁Ph 0.034027099609375
arma 0.01004791259765625
ce 0.0014581680297851562
ut 0.00017714500427246094
ical 0.0002598762512207031
s 0.01202392578125
▁Inc 1.5107421875
.' 0.1802978515625
s 0.0008025169372558594
▁( 5.4375
now 3.763671875
▁Tak 1.771484375
eda 0.0020847320556640625
▁Ph 0.47900390625
arma 0.0034465789794921875
ce 0.007717132568359375
ut 0.00014531612396240234
ical 0.0001119375228881836
▁Co 0.9990234375
. 1.4609375
▁Ltd 0.123291015625
.) 0.126708984375
▁Prin 11.875
om 1.4345703125
ast 0.378173828125
at 0.01479339599609375
. 0.303466796875
▁This 4.7890625
▁means 2.7421875
▁that 0.03607177734375
▁British 0.94970703125
▁Bi 0.0011320114135742188
ote 9.5367431640625e-06
ch 0.0016260147094726562
▁pl 0.00582122802734375
c 5.2809715270996094e-05
▁will 0.345703125
▁need 0.99462890625
▁to 0.0032367706298828125
▁work 3.53125
▁hard 0.2281494140625
▁to 0.0185546875
▁differenti 1.6015625
ate 1.5020370483398438e-05
▁Mar 1.5615234375
im 0.0006222724914550781
ast 0.0016956329345703125
at 0.00019669532775878906
▁from 0.11968994140625
▁its 1.087890625
▁compet 0.309326171875
itors 0.0011262893676757812
▁and 0.84716796875
▁position 3.09375
▁it 1.099609375
▁as 0.018646240234375
▁the 2.203125
▁most 3.251953125
▁effective 0.437744140625
▁M 0.5625
MP 0.0006618499755859375
▁in 0.00638580322265625
hib 9.894371032714844e-06
itor 0.0016489028930664062
. 1.591796875
<0x0A> 0.040740966796875
B 2.302734375
rit 0.02252197265625
ish 0.0008697509765625
▁Bi 0.0024166107177734375
ote 2.6226043701171875e-05
ch 0.0026798248291015625
▁pl 0.0109100341796875
c 4.2438507080078125e-05
▁will 3.02734375
▁need 0.7353515625
▁to 0.0079803466796875
▁invest 3.08203125
▁in 1.693359375
▁market 4.0234375
ing 0.01800537109375
▁and 0.1962890625
▁research 4.19921875
▁and 0.1788330078125
▁development 0.001255035400390625
▁to 0.67236328125
▁ensure 0.85888671875
▁that 0.1798095703125
▁Mar 0.5732421875
im 0.0001876354217529297
ast 0.0010471343994140625
at 9.453296661376953e-05
▁becomes 1.7314453125
▁a 0.06292724609375
▁block 0.69091796875
b 0.00012683868408203125
uster 0.00045013427734375
▁drug 0.0701904296875
. 0.248046875
▁The 0.9716796875
▁company 0.11724853515625
▁will 0.2435302734375
▁need 0.88525390625
▁to 0.006031036376953125
▁conduct 3.828125
▁further 0.8759765625
▁tri 3.220703125
als 2.86102294921875e-06
▁to 0.168701171875
▁demonstrate 0.86767578125
▁the 0.34228515625
▁drug 0.2078857421875
' 0.001155853271484375
s 0.00011861324310302734
▁safety 0.315185546875
▁and 0.003932952880859375
▁effic 0.052154541015625
acy 7.510185241699219e-06
▁and 2.271484375
▁to 1.166015625
▁determine 5.0234375
▁the 0.95556640625
▁optimal 1.3720703125
▁do 1.5361328125
se 1.430511474609375e-06
▁and 0.98974609375
▁treatment 4.29296875
▁for 8.5859375
▁each 2.02734375
▁cancer 1.955078125
▁type 0.880859375
. 0.0291290283203125
▁Additionally 1.3232421875
, 0.0002715587615966797
▁the 1.4306640625
▁company 0.04254150390625
▁will 0.01043701171875
▁need 0.026611328125
▁to 0.0014848709106445312
▁develop 2.068359375
▁strong 4.921875
▁partners 1.4462890625
hips 0.0013103485107421875
▁with 0.08489990234375
▁phys 3.599609375
icians 0.03985595703125
, 2.15625
▁hosp 1.6943359375
it 0.0004184246063232422
als 3.0994415283203125e-06
, 0.031219482421875
▁and 0.0963134765625
▁other 1.65625
▁st 2.693359375
ake 6.9141387939453125e-06
hold 0.0012149810791015625
ers 3.6954879760742188e-06
▁to 0.325439453125
▁ensure 0.5126953125
▁that 0.09613037109375
▁Mar 0.75634765625
im 0.00011909008026123047
ast 0.0010967254638671875
at 0.0001035928726196289
▁is 0.386962890625
▁widely 1.8369140625
▁pres 3.146484375
cribed 0.00020813941955566406
▁and 0.76416015625
▁used 1.0185546875
▁in 3.125
▁the 0.9755859375
▁treatment 0.5458984375
▁of 0.003932952880859375
▁cancer 0.22265625
. 0.61083984375
<0x0A> 0.29296875
Des 3.7890625
p 0.00672149658203125
ite 0.0001289844512939453
▁the 0.64306640625
▁challeng 0.454345703125
es 0.002300262451171875
, 1.5595703125
▁Mar 2.4140625
im 0.00047016143798828125
ast 0.0015964508056640625
at 0.00012600421905517578
' 3.49609375
s 0.0002467632293701172
▁potential 0.54931640625
▁to 0.92626953125
▁become 0.05615234375
▁a 0.01165771484375
▁block 0.02044677734375
b 8.690357208251953e-05
uster 9.632110595703125e-05
▁drug 0.0278167724609375
▁is 0.6123046875
▁significant 2.23046875
. 0.49951171875
▁The 0.78662109375
▁drug 0.27197265625
▁has 0.97216796875
▁demonstrated 1.8330078125
▁prom 0.8203125
ising 1.8715858459472656e-05
▁results 0.042938232421875
▁in 0.0287017822265625
▁Ph 1.7216796875
ase 0.00013017654418945312
▁III 0.0284576416015625
▁clin 0.1114501953125
ical 4.482269287109375e-05
▁tri 0.007030487060546875
als 7.152557373046875e-07
▁and 1.1220703125
▁has 0.75244140625
▁the 0.55126953125
▁potential 0.021026611328125
▁to 0.003082275390625
▁become 2.04296875
▁a 0.1846923828125
▁valuable 2.890625
▁th 1.2021484375
era 2.2649765014648438e-06
pe 2.6226043701171875e-06
ut 2.6702880859375e-05
ic 0.0008726119995117188
▁option 0.04705810546875
▁for 0.01064300537109375
▁cancer 0.40771484375
▁patients 0.0018529891967773438
. 0.10601806640625
▁British 1.0419921875
▁Bi 0.0010280609130859375
ote 7.748603820800781e-06
ch 0.001537322998046875
▁pl 0.0027790069580078125
c 2.6106834411621094e-05
▁must 4.32421875
▁work 1.1318359375
▁hard 0.040191650390625
▁to 0.0028839111328125
▁overcome 3.064453125
▁the 0.271728515625
▁hur 1.138671875
d 5.125999450683594e-06
les 0.0004303455352783203
▁and 1.58203125
▁position 3.796875
▁Mar 0.1580810546875
im 0.00010180473327636719
ast 0.0013904571533203125
at 8.404254913330078e-05
▁as 0.017791748046875
▁the 0.498046875
▁most 0.057342529296875
▁effective 0.004669189453125
▁M 0.0224761962890625
MP 0.0002613067626953125
▁in 0.0025787353515625
hib 1.7881393432617188e-06
itor 0.0004532337188720703
▁on 1.611328125
▁the 0.002391815185546875
▁market 0.0029125213623046875
. 0.0477294921875
▁With 3.20703125
▁the 0.62353515625
▁right 0.1583251953125
▁invest 2.251953125
ment 0.99658203125
▁and 0.490234375
▁strategy 3.0390625
, 0.0115509033203125
▁Mar 0.9345703125
im 0.00016558170318603516
ast 0.001590728759765625
at 4.887580871582031e-05
▁could 0.994140625
▁become 0.2320556640625
▁a 0.1182861328125
▁key 5.57421875
▁player 0.31689453125
▁in 0.0026092529296875
▁the 0.0279998779296875
▁fight 3.505859375
▁against 0.002864837646484375
▁cancer 0.007343292236328125
. 0.1201171875
